Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer. - Wikidata - awgldk - TriplyDB

Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer.

Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer.

http://www.wikidata.org/entity/Q38258744

about

Digitoxin and its synthetic analog MonoD have potent antiproliferative effects on lung cancer cells and potentiate the effects of hydroxyurea and paclitaxel Albumin-Bound Paclitaxel: A Review in Non-Small Cell Lung Cancer.Efficacy and safety of taxane-based systemic chemotherapy of advanced gastric cancer: A systematic review and meta-analysis.Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms Prodrug-based nano-drug delivery system for co-encapsulate paclitaxel and carboplatin for lung cancer treatment.Zinc supplementation induces apoptosis and enhances antitumor efficacy of docetaxel in non-small-cell lung cancer.Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer: A meta-analysis.A methoxyflavanone derivative from the Asian medicinal herb (Perilla frutescens) induces p53-mediated G2/M cell cycle arrest and apoptosis in A549 human lung adenocarcinoma.Gefitinib versus Docetaxel in Treated Non-small-cell Lung Cancer: A Meta-analysis.Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression.

P2860

Q28397351-75DBE99C-B94B-4FD9-A3E6-8F89DA83F489 Q33427359-818A5BE7-0445-4B84-B75F-CBF4D619A442 Q33902814-66A86214-E436-467B-A752-876E3B8E502E Q36751705-803A3A3E-45F2-4F1C-AC9B-E6B4959E2588 Q38741016-71A52E0B-1093-4491-A911-4ED30596A572 Q38845614-F423A516-5F75-4BB7-8319-94E86F5FD9A9 Q42359608-A31908F4-08A0-4254-9FFE-DFC5D3097E0D Q48121657-4F41162E-99E2-44F3-88C8-B58120DA1304 Q54153582-DCE3BB23-D3CC-4D1C-87ED-19A480E5D036 Q55561847-0AE91838-101A-4172-AC2F-21C9DEAC6B78

P2860

Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer.

http://www.wikidata.org/entity/Q38258744

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer.

@en

type

label

Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer.

@en

prefLabel

Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer.

@en

P1433

Q38258744-571D4A12-C803-425B-9C21-4D01BBD99F6E

P1476

Q38258744-6C509BAB-66CC-4E2C-9456-D9C2FE017EAC

P2093

Q38258744-2BB7366A-F8C2-4DF0-9BAC-85AF8F16705C

P2860

Q38258744-02789438-ED38-44E7-B337-58D5BE7049BB

Q38258744-037F6B80-16C0-4FEF-9498-890E9764CEE4

Q38258744-06C5BF6E-3265-4BDE-AB0B-C3A02F233874

Q38258744-08DFBF19-8841-425F-8B1B-41456A7062A3

Q38258744-15E50E07-BF25-4B76-AF3B-15D1867E88ED

Q38258744-15ECF9D7-EF19-41FA-AFAC-D0A6542D3BD4

Q38258744-1AC1C8A9-69D5-4955-8A05-5A514235954D

Q38258744-20C4C692-5A9F-4782-A380-676D905D608D

Q38258744-20C85FBF-E87A-4F23-BB84-B6C80C76C33C

Q38258744-21EB7816-2BBE-458C-816B-39D117F60155

P304

Q38258744-B94E6F59-3573-40FD-8FA4-6915EF1F6BFB

P31

Q38258744-5563B04E-D637-475E-A6FC-D2E33C6550CA

P356

Q38258744-A4A10693-D279-489E-AA9B-208D40FFC320

P433

Q38258744-0940AB81-987D-441D-946D-EF5FB1756CB0

P478

Q38258744-50644AB9-6CDA-416A-8613-65F9344F54CE

P577

Q38258744-EAE1A976-4953-421E-B15C-8DBD10E4F907

P5875

Q38258744-69B8B1E3-0BD5-4BEB-B071-20F6CCF61EE3

P698

Q38258744-300725BD-387F-4739-A6C3-7C0B881B333D

P921

Q38258744-8FC83BE1-CC6E-4B92-9C69-B1B9F60CEF5E

P932

Q38258744-92ADB18E-9227-49CF-85F5-50CD59BFAEF2

P356

P1433

Current Oncology

P1476

Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer.

@en

P2093

M A Socinski

http://www.w3.org/2001/XMLSchema#string

P2860

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Erlotinib in previously treated non-small-cell lung cancer

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.

Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.

Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial.

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.

P304

e691-703

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3747/CO.21.1997

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266746988

http://www.w3.org/2001/XMLSchema#string

P698

25302040

http://www.w3.org/2001/XMLSchema#string

P921

P932

4189574

http://www.w3.org/2001/XMLSchema#string